Surgery: light – thermal – and electrical application – Light – thermal – and electrical application – Thermal applicators
Reexamination Certificate
2000-06-08
2003-02-18
Gibson, Roy D. (Department: 3739)
Surgery: light, thermal, and electrical application
Light, thermal, and electrical application
Thermal applicators
C607S114000
Reexamination Certificate
active
06520982
ABSTRACT:
RELATED APPLICATION INFORMATION
This invention relates generally to devices for applying localized liquid therapy and/or thermotherapy to an afflicted area of an afflicted patient. More particularly, this invention relates to a device, and method of use therefor, which directly applies a liquid, most usually a water based liquid to a selected area to create the desired therapeutic effect, most usually a localized hyperthermia, which is effective in treating localized afflictions such as moles, lesions, tumors, malignancies, both surface and subcutaneous, and the like, or a therapeutic lavage or irrigation.
BACKGROUND OF THE INVENTION
Heat and cold have both been used to effectively treat afflicted patients. Directly applying liquid to afflicted cells is also well known. Cold has often been used as a localized treatment, while heat has been, and is currently, used as both a localized and total body treatment. Using heat to treat a localized afflicted area of an afflicted patient is most relevant to the present invention.
The search continues for ways to effectively treat wounds, tumors and similar disorders while minimizing adverse collateral effects. For example, assignee has been a leader in treating open wounds through a process known as Vacuum Assisted Closure, “V.A.C.” which is not believed to have any adverse collateral effects. In a similar vein, for certain conditions, localized thermotherapy, primarily localized hyperthermia, has also shown promise as a treatment modality which is capable of producing beneficial therapeutic effects without significant adverse collateral effects. However, the localized hyperthermic treatment modalities in the prior art, all suffer from serious drawbacks, limitations, or side effects.
Research has demonstrated that heating cancerous, or other abnormal cells to over about 42 degrees C. can kill the abnormal cells, while causing little damage to the surrounding normal cells. This treatment is temperature sensitive. Heating the cancer cells, for example, to a temperature between nominal body temperature, 37 degrees C. and approximately 41 degrees C., can actually promote their cellular growth. Heating healthy cells to approximately 45 degrees C. or greater can seriously damage them. To maximize patient safety, this hyperthermia treatment must be localized.
The variety of available heat transfer methods for localized thermotherapy are limited. Heat is transferred in three ways, radiation, convection, or conduction. The heat transfer medium creating the localized hyperthermia can either be heated in situ or be heated exogenously, before being placed upon the patient. The medium can either be placed in direct contact with the afflicted cells or, transfer heat to the afflicted cells through an intermediary.
Localized hyperthermia therapy is presently used in treating prostate afflictions, breast cancer, and likely other afflictions. This modality involves placing implants about the afflicted patient's afflicted cells, and then heating the implants by radiating EMF or ultrasonic energy thereto. The heat from the implants then migrates into the afflicted tissue, via conduction, thereby raising the temperature of the afflicted cells. Several issued patents demonstrate variations of this technique. Issues relating to possible adverse affects of exposure to both radiation, and radiated energy abound. However, as most sufferers of prostate cancer are older men who are past the age of fathering children, and female breasts are relatively remote from the female reproductive organs, the possible long-term adverse collateral effects of using such radiant energy treatments are minimized.
Applicant has discovered various patents that employ and exemplify, other energy transfer methods, and media, in creating localized hyperthermias. The first of these patents, Guibert, U.S. Pat. No. 4,595,008, issued Jun. 17, 1986, may be summarized as follows: “ . . . air heated to a temperature well above normal body temperature is projected as a high velocity stream in a pulsatory wave pattern toward a localized skin area overlying a problem region, thereby subjecting this area to high-velocity heated air pulses separated by lower air temperature, relatively static intervals. The pulsatory wave pattern is created by apparatus which operates in a periodic interruption mode, in a cyclical stepping mode or in a cyclical sweeping mode, depending on the nature of the instrument and its intended applications. As a consequence of the pulsatory wave pattern, heat transfer takes places through the body tissue toward the problem region during the intervals between the pulses, this inward transfer acting to reduce the temperature at the skin surface to a degree preventing an undue rise thereof. While during the pulse periods the temperature of the hot air at the skin surface is much higher than body temperature, the duration of each pulse is relatively short and insufficient to cause discomfort or injury to the patient.” Guibert Col. 2 line 61-Col. 3 line 15.
This description shows that Guibert uses a heated fluid to indirectly transfer heat to an afflicted area of a patient; the fluid, air, does not come into contact with the afflicted area. Another device that also uses a heated fluid to treat an afflicted portion of a patient's body is Shantha, U.S. Pat. No. 5,195,965 issued Mar. 23, 1993. Shantha may be summarized as follows: “ . . . the present invention comprises an apparatus for heating the interior surfaces of a hollow organ or orifice, for example the interior surfaces of the reproductive tract of a female human being, for the treatment of viral infections and cancers. For example, the invention is useful for the treatment of Human Papilloma Virus, chlamydia, trichomonas vaginitis, vaginal yeast infections, gonococcus, rectal and anal infections, rectal and anal cancers, esophageal cancer, etc. The apparatus comprises an insertion body having a flexible outer surface and is adapted for insertion into the hollow organ or orifice, such as the female reproductive tract. The insertion body is adapted to contact and conform to the interior surfaces of the hollow organ. The apparatus also includes means for heating the outer surface of the insertion body and for maintaining a selected temperature at the outer surface. Preferably, the insertion body comprises an inflatable outer membrane or balloon supported about a semi-rigid support member. The inflatable balloon is adapted to contain liquid under pressure and the apparatus includes means for circulating liquid between the inflatable balloon and an external heating device. Sensor means are positioned along the outer surface of the inflatable balloon for determining the temperature of the outer surface of the balloon. Control means, responsive to the temperature of the outer surface as determined by the sensor means, are provided for controlling the external heating device so as to maintain the temperature of the outer surface at the selected temperature. With this construction, the inflatable balloon can be inserted into the hollow organ in an uninflated state and subsequently inflated with liquid under pressure. The liquid is then circulated and heated in the external heating device. The liquid, preferably water, is maintained at a temperature of between 40.degree. C. and 44.degree. C. for between 2 and 6 hours. Preferably, the water is maintained at a temperature of 41.8.degree. C. (roughly 107.2.degree. F.), and the inflatable body is maintained in the hollow organ for four (4) hours. Maintaining the inflatable body at 41.8.degree. C. for four (4) hours kills many bacteria, viruses and cancer cells. The immune system of the patient normally is stimulated by the destroyed virus cells, microbes, and cancer cells and attacks any infected or cancerous cells not destroyed by the heat. This temperature of 41.8.degree. C. is low enough that healthy tissue survives relatively undamaged, owing to the lesser heat sensitivity of healthy cells as compared with infected and cancerous cells. The localized nature of the treatme
Boynton Thomas A.
Johnson Royce W.
Gibson Roy D.
KCI Licensing Inc.
LandOfFree
Localized liquid therapy and thermotherapy device does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Localized liquid therapy and thermotherapy device, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Localized liquid therapy and thermotherapy device will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3172627